Report
Retatrutide becomes the first triple-agonist weight-loss drug to reach phase 3
Scientific American describes the experimental drug’s trial as a “new high-water mark” for weight-loss drugs.
TLDR
Scientific American says retatrutide is a triple agonist and the first of its kind to reach a phase 3 clinical trial. It describes the experimental weight-loss drug’s trial as a “new high-water mark” for these medications.
Combined views
19.5K
3 Sources, first seen 1h ago
123 likes
